Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $32.28 billion. The enterprise value is $39.35 billion.
| Market Cap | 32.28B |
| Enterprise Value | 39.35B |
Important Dates
The last earnings date was Wednesday, July 29, 2026, before market open.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 147.75 million shares outstanding. The number of shares has increased by 1.20% in one year.
| Current Share Class | 147.75M |
| Shares Outstanding | 147.75M |
| Shares Change (YoY) | +1.20% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 97.06% |
| Float | 147.22M |
Valuation Ratios
The trailing PE ratio is 38.75 and the forward PE ratio is 16.54. Biogen's PEG ratio is 4.11.
| PE Ratio | 38.75 |
| Forward PE | 16.54 |
| PS Ratio | 3.22 |
| Forward PS | 3.08 |
| PB Ratio | 1.71 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.97 |
| P/OCF Ratio | 11.21 |
| PEG Ratio | 4.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.72, with an EV/FCF ratio of 14.59.
| EV / Earnings | 47.15 |
| EV / Sales | 3.92 |
| EV / EBITDA | 11.72 |
| EV / EBIT | 15.64 |
| EV / FCF | 14.59 |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.87 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 2.40 |
| Debt / FCF | 3.10 |
| Interest Coverage | 8.84 |
Financial Efficiency
Return on equity (ROE) is 4.58% and return on invested capital (ROIC) is 8.86%.
| Return on Equity (ROE) | 4.58% |
| Return on Assets (ROA) | 5.21% |
| Return on Invested Capital (ROIC) | 8.86% |
| Return on Capital Employed (ROCE) | 8.93% |
| Weighted Average Cost of Capital (WACC) | 4.66% |
| Revenue Per Employee | $1.34M |
| Profits Per Employee | $111,280 |
| Employee Count | 7,500 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.93 |
Taxes
In the past 12 months, Biogen has paid $176.80 million in taxes.
| Income Tax | 176.80M |
| Effective Tax Rate | 17.48% |
Stock Price Statistics
The stock price has increased by +60.24% in the last 52 weeks. The beta is 0.16, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +60.24% |
| 50-Day Moving Average | 207.41 |
| 200-Day Moving Average | 189.63 |
| Relative Strength Index (RSI) | 58.30 |
| Average Volume (20 Days) | 752,822 |
Short Selling Information
The latest short interest is 5.19 million, so 3.51% of the outstanding shares have been sold short.
| Short Interest | 5.19M |
| Short Previous Month | 5.45M |
| Short % of Shares Out | 3.51% |
| Short % of Float | 3.53% |
| Short Ratio (days to cover) | 4.35 |
Income Statement
In the last 12 months, Biogen had revenue of $10.03 billion and earned $834.60 million in profits. Earnings per share was $5.64.
| Revenue | 10.03B |
| Gross Profit | 7.85B |
| Operating Income | 2.52B |
| Pretax Income | 1.01B |
| Net Income | 834.60M |
| EBITDA | 3.36B |
| EBIT | 2.52B |
| Earnings Per Share (EPS) | $5.64 |
Balance Sheet
The company has $1.29 billion in cash and $8.36 billion in debt, with a net cash position of -$7.07 billion or -$47.85 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 8.36B |
| Net Cash | -7.07B |
| Net Cash Per Share | -$47.85 |
| Equity (Book Value) | 18.85B |
| Book Value Per Share | 127.61 |
| Working Capital | 3.39B |
Cash Flow
In the last 12 months, operating cash flow was $2.88 billion and capital expenditures -$182.20 million, giving a free cash flow of $2.70 billion.
| Operating Cash Flow | 2.88B |
| Capital Expenditures | -182.20M |
| Depreciation & Amortization | 842.90M |
| Net Borrowing | 1.02B |
| Free Cash Flow | 2.70B |
| FCF Per Share | $18.25 |
Margins
Gross margin is 78.32%, with operating and profit margins of 25.09% and 8.32%.
| Gross Margin | 78.32% |
| Operating Margin | 25.09% |
| Pretax Margin | 10.09% |
| Profit Margin | 8.32% |
| EBITDA Margin | 33.50% |
| EBIT Margin | 25.09% |
| FCF Margin | 26.89% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.20% |
| Shareholder Yield | -1.20% |
| Earnings Yield | 2.59% |
| FCF Yield | 8.35% |
Analyst Forecast
The average price target for Biogen is $236.22, which is 8.11% higher than the current price. The consensus rating is "Buy".
| Price Target | $236.22 |
| Price Target Difference | 8.11% |
| Analyst Consensus | Buy |
| Analyst Count | 35 |
| Revenue Growth Forecast (3Y) | 3.48% |
| EPS Growth Forecast (3Y) | 6.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 2.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 4 |